Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Hamburg, Universität Hamburg, Dissertation, 2022
- Schlagwort
-
Brustkrebs
Krebs
Therapie
- Ereignis
-
Veröffentlichung
- (wo)
-
Hamburg
- (wer)
-
Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
- (wann)
-
2022
- Urheber
-
Ott, Leonie Florence
- Beteiligte Personen und Organisationen
-
Pantel, Klaus
Kehr, Julia
- URN
-
urn:nbn:de:gbv:18-ediss-103209
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ott, Leonie Florence
- Pantel, Klaus
- Kehr, Julia
- Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
Entstanden
- 2022
Ähnliche Objekte (12)
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer